[{"id":"857b7ebe-3cc8-4993-a50e-8caa69d9391d","acronym":"","url":"https://clinicaltrials.gov/study/NCT01526473","created_at":"2021-01-18T06:26:07.269Z","updated_at":"2024-07-02T16:37:12.676Z","phase":"Phase 1","brief_title":"A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901","source_id_and_acronym":"NCT01526473","lead_sponsor":"H. Kim Lyerly","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression • HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AVX901"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 02/01/2012","start_date":" 02/01/2012","primary_txt":" Primary completion: 03/01/2016","primary_completion_date":" 03/01/2016","study_txt":" Completion: 12/01/2017","study_completion_date":" 12/01/2017","last_update_posted":"2018-03-29"}]